Trial Profile
A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFalpha Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms PURSUIT-PEDS-PK
- Sponsors Janssen Research & Development
- 14 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial was completed in Austria, according to European Clinical Trials Database.
- 24 Sep 2019 This trial was completed in Germany, according to European Clinical Trials Database.